280
A. Montero et al. / Tetrahedron Letters 51 (2010) 277–280
22, 83–93; (e) Murphy, P. V.; Dunne, J. L. Curr. Org. Synth. 2006, 3, 403–437; (f)
17. For selected publications on calpain and its inhibitors, see: (a) Goll, D. E.;
Thompson, V. F.; Li, H.; Wei, W.; Cong, J. Physiol. Rev. 2003, 83, 731–801; (b)
Tompa, P.; Buzder-Lantos, P.; Tantos, A.; Farkas, A.; Szilagyi, A.; Banoczi, Z.;
Hudecz, F.; Friedrich, P. J. Biol. Chem. 2004, 279, 20775–20785; (c) Zatz, M.;
Starling, A. N. Eng. J. Med. 2005, 352, 2413–2423; (d) Neffe, A. T.; Abell, A. D.
Curr. Opin. Drug Disc. Devel. 2005, 8, 684–700; (e) Carragher, N. Curr. Pharm.
Des. 2006, 12, 615–638; (f) Croall, D. E.; Ersfeld, K. Genome Biol. 2007, 8, 218.
18. Our previous work has shown the importance of aromatic substitution on
calpain inhibition, see: Montero, A.; Albericio, F.; Royo, M.; Herradon, B. Org.
Lett. 2004, 6, 4089–4092. and references cited therein.
19. For recent examples of biologically active carbohydrates with aromatic
substitution, see: (a) Jacobsson, M.; Ellervik, U.; Belting, M.; Mani, K. J. Med.
Chem. 2006, 49, 1932–1936; (b) Lee, K. Y.; Sung, S. H.; Kim, Y. C. J. Nat. Prod.
2006, 679–681; (c) Saquib, M.; Gupta, M. K.; Sagar, R.; Prabhakar, Y. S.; Shaw, A.
K.; Kumar, R.; Maulik, P. R.; Gaikwad, A. N.; Sinha, S.; Srivastana, A. K.;
Chaturvedi, V.; Srivastana, R.; Srivastana, B. S. J. Med. Chem. 2007, 50, 2942–
2950.
Murphy, P. V. Eur. J. Org. Chem. 2007, 4177–4187; For recent developments, see:
(g) Jockusch, R. A.; Talbot, F. O.; Rogers, P. S.; Simone, M. I.; Fleet, G. W. J.;
Simons, J. P. J. Am. Chem. Soc. 2006, 128, 16771–16777; (h) Sharma, G. V. M.;
Jadhav, V. B.; Ramakrishna, K. V. S.; Jayaprakash, P.; Narsimulu, K.; Subash, V.;
Kunwar, A. C. J. Am. Chem. Soc. 2006, 128, 14657–14668; (i) Paloumbis, G.;
Petrou, C.; Nock, B.; Maina, T.; Pairas, G.; Tsoungas, P.; Cordopatis, P. Synthesis
2007, 845–852; (j) Chakraborty, T. K.; Kumar, S. U.; Mohan, B. K.; Sarma, G. D.;
Kiran, M. U.; Jagadeesh, B. Tetrahedron Lett. 2007, 48, 6945–6950; (k) Maity, P.;
Zabel, M.; Konig, B. J. Org. Chem. 2007, 72, 8046–8053; (l) Risseeuw, M. D. P.;
Mazurek, J.; van Langenvelde, A.; van der Marel, G. A.; Overkleeft, H. S.;
Overhand, M. Org. Biomol. Chem. 2007, 5, 2311–2314; (m) Bughin, C.; Masson,
G.; Zhu, J. J. Org. Chem. 2007, 72, 1826–1829; (n) Chandrasekhar, S.; Saritha, B.;
Naresh, P.; Udayakiran, M.; Reddy, C. R.; Jagadeesh, B. Helv. Chim. Acta 2008, 91,
1267–1276; (o) Tuin, A. W.; Palachanis, D. K.; Buizert, A.; Grotenbreg, G. M.;
Spalburg, E.; de Neeling, A. J.; Mars-Groenendijk, R. H.; Noort, D.; van der Marel,
G. A.; Overkleeft, H. S.; Overhand, M. Eur. J. Org. Chem. 2009, 4231–4241.
8. Montero, A.; Mann, E.; Herradon, B. Eur. J. Org. Chem. 2004, 3063–3073.
9. Montero, A.; Mann, E.; Herradon, B. Tetrahedron Lett. 2005, 46, 401–405.
10. A. Montero, Ph.D. Thesis, Universidad Autónoma de Madrid, 2004.
11. (a) Lubineau, A.; Canac, Y.; Le Goff, N. Adv. Synth. Catal. 2002, 344, 319–327; (b)
Krohn, K.; Flörke, U.; Huele, D. J. Carbohydr. Chem. 2002, 21, 431–443; The
current importance of chiral halogenated chlorides can be exemplified by the
recent synthesis of a chlorosulfolipid cytotoxin, see: (c) Nilewski, C.; Geisser, R.
W.; Carreira, E. M. Nature 2009, 457, 573–577.
12. (a) Carbohydrate in Drug Design; Witczak, Z. J., Nieforth, K. A., Eds.; Marcel
Dekker: NY, 2004; (b) Ernst, B.; Magnani, J. L. Nat. Rev. Drug Disc. 2009, 8, 661–
677.
13. Ager, D. J.; Pantaleone, D. P.; Henderson, S. A.; Katritzky, A. R.; Prakash, I.;
Walters, D. E. Angew. Chem., Int. Ed. 1998, 37, 1802–1817.
20. (a) Mitsunobu, O.; Yamada, M.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 1967, 40,
935–939; (b) Mitsunobu, N. Synthesis 1981, 1–28; (c) Wisniewski, K.;
Koldziejczyk, A. S.; Falkiewicz, B. J. Peptide Sci. 1998, 4, 1–14; (d) Swamy, K.
C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V. P. P. Chem. Rev. 2009, 109,
2551–2651.
21. After our initial disclosure (see footnote no. 10 in Ref. 9), two articles reporting
chlorinated by-products in Overman rearrangement have been published (both
of them missed to cite our former article), see: (a) Pietruszka, J.; Schone, N.;
Frey, W.; Grundl, L. Chem. Eur. J. 2008, 14, 5178–5197; (b) Matveenko, M.;
Willis, A. C.; Banwell, M. G. Aust. J. Chem. 2009, 62, 64–68; (c) A minor mistake
has been detected in the structures drawn in Ref. 9: the protecting group is
TBDPS instead of TBDMS, we apologize for the error.
22. A thorough mechanistic study is underway (de Miguel, I.; Mann, E.; Herradon,
B.). Our preliminary results seem to indicate that the reaction is a SN20 although
the trichloroacetimidate group is essential to achieve the total selectivity
(regio- and stereo-). On the other hand, DBU and trichloroacetonitrile yield a
putative 2:1 DBU-Cl ate complex which is a chlorinating agent, although its
structure has not been yet clarified.
14. (a) Herradon, B.; Valverde, S. Tetrahedron: Asymmetry 1994, 5, 1479–1500; (b)
Herradón, B.; Morcuende, A.; Valverde, S. Synlett 1995, 455–458.
15. Nishikawa, T.; Asai, M.; Ohyabu, N.; Isobe, M. J. Org. Chem. 1998, 63, 188–192.
16. All the new compounds have been fully characterized by spectroscopic and
analytical methods (see Supplementary data).